drugset
Drugs / Anti SARS-CoV-2 equine hyperimmune serum
last change Sep 2021 re-read 3 minutes ago

Anti SARS-CoV-2 equine hyperimmune serum

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
Costa Rican Social Security Fund · Ministry of Health Costa Rica · Universidad de Costa Rica

Trials 1

today NCT04838821 · Ph 2/3
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT04838821 Mar → Jul 2021 COVID-19 Costa Rican Social Security Fund Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Anti SARS-CoV-2 equine hyperimmune serum ClinicalTrials.gov intervention name — accepted as the source's own label NCT04838821 ↗
Modality Protein / enzyme biologic “Equine polyclonal hyperimmune sera is a source of neutralizing antibodies against SARS-CoV-2” NCT04838821 ↗
Route Intravenous “single intravenous infusion” NCT04838821 ↗